重组人血管内皮抑素联合多西紫杉醇方案治疗非小细胞肺癌的临床疗效

Efficacy of YH-16 combined with weekly docetaxel in treating non-small cell lung cancer

目的评价重组人血管内皮抑素(YH-16)联合周剂量多西紫杉醇治疗晚期非小细胞肺癌(NSCLC)的近期临床疗效及安全性。方法 46例晚期复发的NSCLC患者分为治疗组(21例,YH-16+周剂量多西紫杉醇)和对照组(25例,单用多西紫杉醇周剂量方案)。治疗2～4个周期,按照RECIST标准和NCI-CTC3.0标准分别评价其疗效及毒副反应。结果治疗组和对照组有效率分别为19.0%和8.3%(P>0.05),疾病控制率为61.9%和54.2%(P>0.05)。治疗组中位无进展生存期(PFS)明显长于对照组(5.4个月vs.4.5个月)(P<0.01)。两组近期常见的毒副反应相仿(P>0.05)。结论 YH-16联合多西紫杉醇治疗晚期NSCLC能提高患者的无进展生存期,且毒副反应无明显增加。

Objective To evaluate the short-term efficacy and safety of YH-16 combined with weekly docetaxel in second-line treatment of advanced non-small cell lung cancer（NSCLC）.MethodsForty-six NSCLC patients were randomly divided into groups of A（21 cases,treated with YH-16 combined with docetaxel weekly for 2 to 4 cycles） and B（25 cases,docetaxel alone）.The efficacy and toxicity were evaluated according to RECIST and NCI-CTC3.0 criteria.Results The effectiveness rates of groups of A and B were similar（19.0% vs.8.3%）（P0.05）.So did the disease-controlled rates（61.9% vs.54.2%）（P0.05）.The median progression-free survival（PFS） in group A was 5.4 months,which was longer than 4.5 months in group B（P0.01）.The incidence of common toxicity of two groups were similar（P0.05）.Conclusion YH-16 combined with weekly docetaxel may prolong PFS without increase of adverse effects in patients with NSCLC.